Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU.

[1]  T. Warkentin.  Heparin-induced thrombocytopenia. , 2002, Disease-a-month : DM.

[2]  J. Baker,et al.  Lack of Value of Clinical Predictors of Heparin Induced Thrombocytopenia (HIT) in Complex Patients. , 2004 .

[3]  J. Kelton,et al.  Laboratory Testing for Hit Antibodies: How Much Class Do We Need?. , 2004 .

[4]  Y. Gruel,et al.  The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. , 2004, Blood.

[5]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[6]  G. Guyatt,et al.  The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy , 2004 .

[7]  A. Greinacher,et al.  Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[8]  T. Warkentin.  An overview of the heparin-induced thrombocytopenia syndrome. , 2004, Seminars in thrombosis and hemostasis.

[9]  C. Kitchens.  Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin‐induced thrombocytopenia , 2004, American journal of hematology.

[10]  G. Guyatt,et al.  Thrombocytopenia in medical–surgical ICU patients , 2004, Critical Care.

[11]  D. Hoppensteadt,et al.  Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis , 2004, Molecular and Cellular Biochemistry.

[12]  C. Dempfle.  Coagulopathy of sepsis , 2004, Thrombosis and Haemostasis.

[13]  T. Warkentin.  Laboratory Testing for Heparin-Induced Thrombocytopenia , 2000, Journal of Thrombosis and Thrombolysis.

[14]  T. Warkentin.  Pseudo–Heparin-Induced Thrombocytopenia , 2003 .

[15]  G. Denomme.  The Platelet Fc Receptor in Heparin-Induced Thrombocytopenia , 2003 .

[16]  T. Warkentin,et al.  Frequency of Heparin-Induced Thrombocytopenia , 2003 .

[17]  D. Cook,et al.  Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study. , 2003, Journal of critical care.

[18]  J. Hirsh,et al.  An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. , 2003, Archives of internal medicine.

[19]  A. Greinacher,et al.  Heparin-induced thrombocytopenia and cardiac surgery. , 2003, The Annals of thoracic surgery.

[20]  J. Kelton,et al.  Frequency of Heparin‐Induced Thrombocytopenia in Critical Care Patients , 2003, Pharmacotherapy.

[21]  T. Warkentin,et al.  Heparin‐induced thrombocytopenia: pathogenesis and management , 2003, British journal of haematology.

[22]  T. Warkentin.  Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. , 2003, Thrombosis research.

[23]  P. Prandoni,et al.  The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. , 2003, Blood.

[24]  M. Aschermann,et al.  Severe acute mitral regurgitation complicating acute myocardial infarction: case for aggressive therapy , 2003, Critical Care.

[25]  N. Heddle,et al.  Laboratory diagnosis of immune heparin-induced thrombocytopenia. , 2003, Current hematology reports.

[26]  D. Hoppensteadt,et al.  Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. , 2002, Thrombosis research.

[27]  E. Lindhoff‐Last,et al.  Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin , 2002, British journal of haematology.

[28]  C. Koebnick,et al.  Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome* , 2002, Critical care medicine.

[29]  J. Spinelli,et al.  Risk Markers for Thrombocytopenia in Critically Ill Patients: A Prospective Analysis , 2002, Pharmacotherapy.

[30]  D. Cook,et al.  Venous thromboembolism and its prevention in critical care. , 2002, Journal of critical care.

[31]  M. Kollef,et al.  Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis , 2002, Critical care medicine.

[32]  M. Poncz,et al.  Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. , 2002, Blood.

[33]  D. Cook,et al.  Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study. , 2001, Journal of critical care.

[34]  D. Cook,et al.  Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey , 2001, Critical care.

[35]  G. Arepally,et al.  Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. , 2001, Blood.

[36]  R. Aster,et al.  Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. , 2001, The Journal of laboratory and clinical medicine.

[37]  H. Ackermann,et al.  Determination of heparin–platelet factor 4–IgG antibodies improves diagnosis of heparin‐induced thrombocytopenia , 2001, British journal of haematology.

[38]  D. Cook,et al.  Deep vein thrombosis and its prevention in critically ill adults. , 2001, Archives of internal medicine.

[39]  J. Kelton,et al.  Temporal aspects of heparin-induced thrombocytopenia. , 2001, The New England journal of medicine.

[40]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[41]  J. Morris,et al.  Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. , 2001, Mayo Clinic proceedings.

[42]  Kovacs Ka,et al.  Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. , 2001 .

[43]  M. Meade,et al.  Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. , 2000, Journal of critical care.

[44]  P. Horsewood,et al.  Impact of the patient population on the risk for heparin-induced thrombocytopenia , 2000 .

[45]  Y. Gruel,et al.  Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation , 2000, British journal of haematology.

[46]  R. Pordes,et al.  Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. , 2000, American journal of respiratory and critical care medicine.

[47]  J. Moran,et al.  Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. , 1999, The American journal of medicine.

[48]  P. Mismetti,et al.  Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. , 1999, Chest.

[49]  Y. Gruel,et al.  Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. , 1999, Circulation.

[50]  J. Herbert,et al.  Effect of SR121566A, a Potent GP IIb-IIIa Antagonist, on the HIT Serum/heparin-Induced Platelet Mediated Activation of Human Endothelial Cells , 1998, Thrombosis and Haemostasis.

[51]  A. Greinacher,et al.  Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. , 1998, Blood.

[52]  S. Trottier,et al.  Utilization of venous thromboembolism prophylaxis in a medical-surgical ICU. , 1998, Chest.

[53]  J. Kelton,et al.  The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia , 1997, Annals of Internal Medicine.

[54]  B. A. Boucher,et al.  Critical Care: Incidence and Risk Factors of Thrombocytopenia in Critically Ill Trauma Patients , 1997, The Annals of pharmacotherapy.

[55]  J. Kelton,et al.  A 14-year study of heparin-induced thrombocytopenia. , 1996, The American journal of medicine.

[56]  J. Szalai,et al.  A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. , 1996, The New England journal of medicine.

[57]  K. Kier,et al.  Thrombocytopenia in Intensive Care Patients: A Comprehensive Analysis of Risk Factors in 314 Patients , 1995, The Annals of pharmacotherapy.

[58]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[59]  R. Rao,et al.  Bilateral massive adrenal hemorrhage. , 1995, The Medical clinics of North America.

[60]  J. Kelton,et al.  Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. , 1994, Blood.

[61]  E. Ingenito,et al.  Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. , 1994, Chest.

[62]  A. Greinacher,et al.  Laboratory diagnosis of heparin‐associated thrombocytopenia and comparison of platelet aggregation test, heparin‐induced platelet activation test, and platelet factor 4/heparin enzyme‐linked immunosorbent assay , 1994, Transfusion.

[63]  B. Chong,et al.  Plasma P-selectin is increased in thrombotic consumptive platelet disorders , 1994 .

[64]  R. Baughman,et al.  Thrombocytopenia in the intensive care unit. , 1993, Chest.

[65]  B. Chong,et al.  Increased expression of platelet IgG Fc receptors in immune heparin-induced thrombocytopenia. , 1993, Blood.

[66]  J. Kelton,et al.  Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. , 1992, The Journal of laboratory and clinical medicine.

[67]  J. Kelton,et al.  Heparin-induced thrombocytopenia: laboratory studies. , 1988, Blood.

[68]  J. Cade.  High risk of the critically ill for venous thromboembolism , 1982, Critical care medicine.